key: cord-0906217-jewz87qf authors: Brunetti, Natale Daniele; Poliseno, Mariacristina; Bottalico, Irene Francesca; Centola, Antonio; Montemurro, Laura; Sica, Salvatore; Santantonio, Teresa; Caputo, Sergio Lo title: Safety and heart rate changes in Covid-19 patients treated with Remdesivir date: 2021-09-20 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.09.036 sha: fa55eebdacef9da6055fa668ac486a1c8313d4ad doc_id: 906217 cord_uid: jewz87qf Objectives Limited data are available regarding the occurrence and the extent of cardiac rhythm disturbances in patients with COVID-19 treated with Remdesivir. Methods Here we present a case series of 52 patients who underwent daily electrocardiogram (ECG) examination after Remdesivir administration. Results Compared to baseline, a significant heart rate reduction was observed after initiation of Remdesivir; no case of severe bradycardia or arrhythmias leading to significant clinical complications or Remdesivir discontinuation however occurred. Heart rate reduction was proportional to baseline heart rate values (r=0.75, p<0.001). At multivariate analysis less severe clinical presentation of Covid-19 (beta=0.47, p<0.01) was related to lower heart rate levels observed after Remdesivir administration. Conclusions. Despite a significant reduction in heart rate observed after Remdesivir administration, no serious cardiovascular toxicity was observed in Covid-19 patients, even in case of cardiovascular comorbidities. (1) Title Running title: "Heart rate and Remdesivir". Remdesivir is the only antiviral drug currently approved under emergency use authorization for the treatment of patients hospitalized for mild and moderate COVID-19 (Beigel et al., 2020) . Isolated cases of cardiac rhythm abnormalities have been reported in patients on Remdesivir, including sinus bradycardia and QTc interval-prolongation (Gubitosa et al., 2020; Gupta et al 2020) warranting for close cardiac rhythm monitoring during Remdesivir administration. We therefore aimed to prospectively assess in a cohort of Covid-19 patients treated with Remdesivir the occurrence of heart rate abnormalities and their potential clinical predictors through serial electrocardiogram examination. From October 1 2020 to February 28 2021, 52 consecutive patients with COVID-19 treated with Remdesivir underwent serial electrocardiogram examination after antiviral administration. Electrocardiograms were recorded at baseline (T0), each day for the following 5 days (T1-T5), and at discharge (Td). Minimum, maximum, and heart rate changes over time, were collected. The occurrence of bradycardia, symptomatic bradycardia, QTc prolongation and of cardiac rhythm abnormalities of any kind were reported. Bradycardia was defined as a heart rate<60 bpm, in accordance with the definition of National Institute of Health (Rijnbeek et al. 2014) . Symptomatic bradycardia was intended as the association of a heart rate <60 bpm and the development of clinical manifestations of syncope or presyncope, transient dizziness or lightheadedness, heart failure symptoms, or confusion states resulting from cerebral hypoperfusion attributable to slow heart rate (Kusumoto et al., 2019) . The occurrence of brady-arrhythmias (sinus pause, sinus node arrest, tachycardia-bradycardia, atrioventricular block, atrial flutter, atrial fibrillation was also noted. For each patient, duration of QT interval at every ECG was recorded in the case report form. Corrected QT (QTc) was calculated in relation to heart rate according to Bazett's formula (Bazett, 1920) . QTc prolongation was defined as the detection of values above the normal range (440 msec for men, 460 msec for women) (Crotti, 2013) . Remdesivir was discontinued in the case of i) clinical signs of symptomatic bradycardia (as defined above) or ii) laboratory findings of worsened kidney and/or liver function were noticed by the attending physician. A global evaluation of the patient's condition that kept age, severity of disease, comorbidities, comedications into account was also requested. Patient were enrolled in the study at the condition of having at least three ECG performed in course of Remdesivir, beside those recorded the days of admission and discharge. Mean hospital stay was 18±9 days, 56% of patients enrolled were male, 76% were >50-year old, 53% had at least one major cardiovascular comorbidity, 57% were hypertensive, 24% diabetes, 7% ischemic heart disease, 77% (N 40) a severe clinical presentation of Covid-19. All but one of the patients were discharged alive; one patient died for septic shock. A median of 5 ECG (IQR 2) per patient were overall recorded in the study population. Compared to baseline, a significant reduction of heart rate was observed after administration of Remdesivir (ANOVA p<0.05, Figure 1a ) from 85±16 bpm at baseline to 70±18 bpm at discharge; heart rate reduction was statistically significant already at first days of treatment (ANOVA p<0.001). No case of symptomatic bradycardia or arrhythmias leading to clinical complications or Remdesivir discontinuation was observed. No case of QTc prolongation occurred. Mean lowest heart rate recorded was 61±11 bpm, mean heart rate reduction observed was 24±16 bpm: mean heart rate reduction was higher in men than in woman (28±16 bpm vs 18±14 bpm, p<0.05). Heart rate reduction was proportional to baseline heart rate values (r=0.75, p<0.001, Figure 1b ). At multivariate analysis including age, gender, cardiovascular risk factors, presence of ischemic heart disease, atrial fibrillation, baseline heart rate, troponin, renal function values, cardiovascular therapy (beta-blockers, amiodarone), and need for ventilation, less severe clinical presentation of p<0 .01) was the only factor significantly related to lower heart rate levels observed after Remdesivir administration. Cardiovascular implications of Sars-COV-2 infection have been widely documented and associated to poor prognosis, that can be worsened by underlying cardiovascular diseases (Azavedo, 2021). Assessing potential adjunctive drug-related cardiovascular toxicity is thus crucial, especially in absence of data regarding the cardiovascular toxicity of some of the few therapeutic options available such as Remdesivir, an antiviral prodrug polymerase with inhibitory activity against the viral RNA-dependent, RNA polymerase of SARS-CoV virus (Beigel et al., 2020) . Studies in vitro demonstrated a great affinity of Remdesivir for human cardiomyocytes, with higher local concentrations and activity (Choi et al., 2020) , partly explaining reported pro-arrhythmic activity of Remdesivir. The potential effect of five-day treatment with Remdesivir on cardiac rhythm has been already highlighted. Beside isolated reports of transient bradycardia, detected through bare clinical observation or with a single ECG performed in the course of antiviral treatment (Barkas et al., 2021 , Gubitosa et al., 2020 , in several cohort studies heart rate was monitored by waist pulse before and during Remdesivir administration (Pallotto et al., 2021) or, just two ECGs were collected before and after antiviral treatment (Attena et al., 2021) . In this paper, data collected from a cohort of patients who underwent daily ECG monitoring in course of Remdesivir administration are presented. Our data seem to confirm previous observations on heart rate reduction after Remdesivir administration, however never associated to bradycardia, symptomatic bradycardia or significant QTc prolongation leading to Remdesivir discontinuation. Notably, higher heart rate reduction was observed in subjects with higher baseline heart rate, thus supporting the hypothesis that principal driver in heart rate reduction was not Remdesivir but, presumably, the improvement in baseline clinical conditions responsible for tachycardia (fever, hypoxia, inflammation, anxiety). Moreover, the phenomenon was especially observed in patients with less severe clinical presentation, a finding that could further reassure clinicians about the absence of contraindications about the use of Remdesivir in critical patients, at least in regard to cardiac function. Accordingly, no significant correlation was observed with age, cardiovascular risk factors and comorbidities, cardiovascular drugs, or troponin levels. The limited number of subjects and the absence of a Remdesvir-free control arm are the main limitations of this study. Nevertheless, as far as can be observed in our sample, Remdesivir showed a favorable toxicity profile even though associated with significant heart rate reduction. Further however research is needed to confirm this preliminary observation on a larger number of subjects. Despite a significant reduction in heart rate observed after Remdesivir administration, no serious cardiovascular toxicity was observed in Covid-19 patients, even in case of cardiovascular comorbidities. None to disclose. No funding received. This is an observational study waived from ethics committee approval. All participants gave a written informed consent. b) Changes in heart rate after Remdesivir were proportional to baseline levels. Remdesivir-Induced Bradycardia in COVID-19: A Single Center Prospective Study Covid-19 and the cardiovascular system: a comprehensive review Sinus Bradycardia Associated with Remdesivir Treatment in COVID-19: A Case Report and Literature Review An analysis of time relations of electrocardiograms Remdesivir for the Treatment of Covid-19 -Final Report Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes COVID-19) Treatment Guidelines. National Institutes of Health 2020 Condizioni cliniche associate ad anomalie dell'intervallo QT: implicazioni cliniche Marked Sinus Bradycardia Associated With Remdesivir in COVID-19: A Case and Literature Review Cardiac Adverse Events With Remdesivir in COVID-19 Infection ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19) Normal values of the electrocardiogram for ages 16-90 years